Market open
Medpace/$MEDP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,900
Website
Medpace Metrics
BasicAdvanced
$10B
26.88
$12.63
1.36
-
Price and volume
Market cap
$10B
Beta
1.36
52-week high
$459.77
52-week low
$302.01
Average daily volume
297K
Financial strength
Current ratio
0.932
Quick ratio
0.896
Long term debt to equity
15.291
Total debt to equity
15.291
Management effectiveness
Return on assets (TTM)
14.87%
Return on equity (TTM)
58.42%
Valuation
Price to earnings (TTM)
26.879
Price to revenue (TTM)
4.983
Price to book
12.57
Price to tangible book (TTM)
80.56
Price to free cash flow (TTM)
18.364
Growth
Revenue change (TTM)
11.84%
Earnings per share change (TTM)
42.23%
3-year revenue growth (CAGR)
22.68%
3-year earnings per share growth (CAGR)
37.96%
What the Analysts think about Medpace
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Medpace Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Medpace Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Medpace News
AllArticlesVideos
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Accesswire·2 days ago
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
Accesswire·4 days ago
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Accesswire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $10B as of February 27, 2025.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 26.88 as of February 27, 2025.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of February 27, 2025.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.